CareLit · DOI-Nachweis · Klinische Pädiatrie
Long-term administration of the tyrosine kinase inhibitor bosutinib via micro-osmotic pumps and resulting skeletal side effects in juvenile rats
DOI 10.1055/s-0033-1343624
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJT Tauer, R Jung, M Suttorp
ZeitschriftKlinische Pädiatrie
Ausgabe05/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: In Ph+ chronic myeloid leukemia the up-regulated BCR-ABL1 tyrosine kinase (TK) is the major target of TK-inhibitors (TKI) like imatinib and dasatinib. Bosutinib is a third generation dual TKI – developed to overcome resistance to first and second generation TKIs – inhibiting Abl and also Src kinases. However, first and second generation TKIs show off-target effects on bone metabolism. Skeletal side effec…
Zitieren
Zitierempfehlung
JT Tauer, R Jung, M Suttorp (2013) Long-term administration of the tyrosine kinase inhibitor bosutinib via micro-osmotic pumps and resulting skeletal side effects in juvenile rats. Klinische Pädiatrie (05). https://doi.org/10.1055/s-0033-1343624
Mit CareLit weiterarbeiten